Company: Novartis
Tags: territory, general
Genuinely curious what Novartis reps are doing to hold Cosentyx share against Skyrizi and Taltz right now. My accounts are getting crushed by AbbVie's pull-through support and the PASI 100 messaging. Cosentyx still owns ankylosing spondylitis in my territory but in plaque psoriasis it's getting harder to get a fair hearing. I've been leaning into the IL-17 dosing flexibility angle but I'm not sure it's moving the needle. Anyone found a clinical angle that actually resonates with dermatologists in 2026? Or are we just managing decline in derm while holding AS? Honest takes only.
13 upvotes · 0 comments